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ABSTRACT 
 
Attenuated response of hippocampal AMPK 
: a neurometabolic account of cognitive aging 
 
 
Sooah Jang 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Eosu Kim) 
 
   Cognitive aging may be caused by aging-associated impairment in neuronal 
energy metabolism. AMP-activated protein kinase (AMPK) plays a pivotal role 
in regulating energy homeostasis, and its adequate activation is crucial to meet 
metabolic demands. However, it has been found that the sensitivity of AMPK 
is decreased during aging in responding to an activator or energy stress in 
peripheral tissues. This may explain bioenergetic failures seen in various organs 
during aging. So I aimed to see whether the responsiveness of AMPK is also 
diminished in the aging brain, and thereby associated with cognitive aging. I 
intraperitoneally administered 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR; AMPK activator) or saline (sham) to young (16-week-
old) and old (72-week-old) mice and measured daily cognitive performances 
using the eight-arm maze. AICAR improved overall cognition in young, but not 
 2 
old, mice, suggesting a blunted effect of AMPK activation on cognition in old 
mice. AICAR-induced changes in AMPK activity were observed in the 
hippocampus of young mice after acute intracerebroventricular (i.c.v.) injection. 
However, neither subchronic nor acute treatment induced significant changes 
in AMPK activity in old mice. Intriguingly, directions of AICAR-induced 
changes in AMPK activity were opposite between the hippocampus (decrease) 
and skeletal muscle (increase). Moreover, hippocampal AMPK activity was 
inversely correlated with cognitive scores. I hypothesized that higher energy 
levels successfully achieved by AICAR treatment might be the reason for 
deactivated neuronal AMPK in young mice. In experiment of acute i.c.v. 
injection of AICAR, as expected, ATP levels were inversely correlated with 
hippocampal AMPK activity, suggesting that it was ATP which mediated 
cognitive improvement by AICAR. Consequences of attenuated response of 
AMPK were also identified in terms of neurogenesis and brain-derived 
neurotrophic factor (BDNF) expression, both of which were also increased only 
in young mice treated with AICAR. The results of my study show that blunted 
response of neuronal AMPK might be a neurometabolic account of cognitive 
aging as a composite result from inadequate mobilization in ATP, BDNF, and 
neurogenesis. These findings suggest that, as well as activating AMPK, 
recovering its sensitivity may be also required to ameliorate cognitive decline 
with aging. 
 
 
Key words: AMPK, Cognitive aging, Neurometabolism, Neurogenesis, BDNF, 
Hippocampus  
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Attenuated response of hippocampal AMPK:  
a neurometabolic account of cognitive aging 
 
Sooah Jang 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Eosu Kim) 
 
 
 
I. INTRODUCTION 
 
 
1. Cognitive aging  
 
  Cognitive aging implies the cognitive state influenced by age itself, which is 
not only quantitatively, but also qualitatively different from dementia.1 With an 
increase of aged population, cognitive decline with aging becomes a highly 
concerning issue in that it can affect quality of life and health outcomes of the 
elderly, especially in those whose cognitive decline is below the threshold for the 
diagnosis of dementia.2 The prevalence of cognitive impairment without 
dementia is higher than that of dementia3; therefore, developing strategies to slow 
the cognitive aging process could have a considerable impact on our aging society. 
Possible contributors for non-pathological cognitive aging such as genetic, 
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general medical, physiological, dietary and lifestyle has been widely studied.4 
However, unfortunately, neurobiological underpinning of cognitive aging still 
remains elusive, primarily because a number of factors influence the complex 
process of brain aging. 
 
A. Cognitive aging and energy metabolism 
  General aging is characterized by energy deficiency.5 Likewise, cognitive 
aging can be explained by dysfunctional energy metabolism in the brain. This 
hypothesis is supported by neuroimaging studies, which revealed that several 
regions of the brain show mild hypometabolism during the progression of normal 
aging.6,7 An experimental study also shows that energy dysfunction can cause 
impairment in neurogenesis, synaptic plasticity and following memory 
impairment that is typical in the aging brain.8-10 Thus, factors that are critically 
involved in energy metabolism could be a target of interest in research on 
cognitive aging.11 
 
2. Age-related decreased neurogenesis and metabolism 
 
Adult neurogenesis in the hippocampus has been known as an essential factor 
of cognitive function.12 This occurs throughout the life span, however its rate 
declines with increasing age, which is deeply related with cognitive aging.13 The 
aging-associated reduction in adult neurogenesis is partly explained by decline in 
responsiveness of neural stem cells to various environmental cues such as 
metabolic stimulation by several growth factors.13-17 Recently, dysfunctional 
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energy metabolism has emerged as a key factor for reduced adult neurogenesis.17 
For example, studies have shown that several conditions causing resistance to 
metabolic signaling, such as high-fat diet, obesity or type 2 diabetes mellitus, lead 
to impaired neurogenesis,18-21 while improving energy metabolism by exercise or 
calorie restriction contributes to enhanced neurogenesis.22,23 In this regard, aging-
related decline in neural responsiveness to metabolic stimuli might be associated 
with diminished neurogenesis in old age.13,24 
 
3. AMPK  
 
A. General structure and function 
AMP-activated protein kinase (AMPK) is a pivotal enzyme regulating energy 
metabolism.25,26 AMPK is a heterotrimer complex composed of a catalytic alpha 
subunit with a conventional kinase domain, and two regulatory subunits, beta and 
gamma.25 It was first discovered as a protein kinase associated with acetyl-CoA 
carboxylase and HMG-CoA reductase, which were respectively the rate-limiting 
regulatory enzymes for fatty acid and cholesterol synthesis.27,28 After that, this 
enzyme was known as regulated by “adenylate energy charge”, which implies 
allosterical modulation by the ratio of [ATP]/[ADP][AMP].29 In other words, this 
enzyme senses the ATP:AMP ratio in cells to maintain energy homeostasis. When 
the ATP:AMP ratio decreases (i.e., there is an energy deficiency), AMPK is 
activated to enhance cellular catabolism, which results in a net increase in ATP 
levels.30 Conversely, when ATP:AMP ratio increases (ATP abundance), AMPK is 
deactivated, which implies sufficient cellular energy. As expected, altered 
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functionality of AMPK has been associated with multiple metabolic disorders, 
such as obesity, type 2 diabetes, and cardiovascular disorders.31-33 
 
B. AMPK and cognitive function 
AMPK also plays a key role for metabolic control in neurons, which are 
metabolically highly active, but have low capacity for nutrient storage.34 In 
accordance with an importance of AMPK in the brain, several studies have 
demonstrated a positive effect of AMPK activation on cognitive function. 
Activation of neuronal AMPK by various stimuli such as drug, natural compound, 
exercise, dietary restriction or electroacupuncture improved cognitive function in 
animal studies.35-39 In a population study, a genetic polymorphism of AMPK is 
associated with cognitive impairment in the community-dwelling elderly.40 These 
results indicated that intact activity of AMPK would be important for 
maintenance of cognitive function. 
 
C. AMPK and neurogenesis 
  Consistent with such an involvement in cognitive function, neuronal AMPK is 
significantly associated with neurogenesis.34,35 Previous studies have shown that 
activation of neuronal AMPK by 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR; an AMPK activator) enhances neurogenesis as well as 
cognitive function in rodents.35,36,41 Also, neuronal AMPK is among key signaling 
pathways to expression of brain-derived neurotrophic factor (BDNF), an essential 
mediator for neurogenesis.42,43 Such an involvement of AMPK in neurogenesis 
might mediate relationship between AMPK and cognitive function. 
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D. Changes of AMPK activity by aging 
  Interestingly, it has been found that, in peripheral tissues, responsiveness of 
AMPK to various stimuli is attenuated in old age.44-46 For example, activation of 
muscular AMPK in response to AICAR or exercise was blunted in old mice in 
contrast with its successful activation leading to increased mitochondrial 
biogenesis in young mice.46 Consistently, AMPKα2 activity measured upon 
exercise training was lower in old than young individuals.44 
 
4. Aims of this study 
 
Discovering neurobiological underpinning of cognitive aging would be an 
essential research in aging society. Recently, metabolic failure of brain has known 
to be largely responsible for cognitive aging, as general aging is mainly caused 
by metabolic dysfunction.  
 
AMPK is a pivotal enzyme for metabolic homeostasis of cell as well as 
organism. Moreover, neuronal AMPK activity plays an active part in maintenance 
of cognitive function and neurogenesis. Such an AMPK activity has found to be 
blunted in old age, and this attenuated AMPK activity has influenced on function 
of the organ, which were identified in peripheral tissues. However, to my 
knowledge, few experimental studies have shown directly whether neuronal 
AMPK action is indeed attenuated during aging and such attenuation is related to 
cognitive aging.  
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  Therefore, I aimed to examine the effect of aging on sensitivity of neuronal 
AMPK in responding to its activator, and the association of AMPK activity with 
cognition as well as with other cognitive effectors such as BDNF and 
neurogenesis in young versus old mice 
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II. MATERIALS AND METHODS 
 
1. Animals and drug treatment 
 
  Young (16-week-old) and old (72-week-old) male C57BL/6 mice (Animal 
Facility of Aging Science, Kwangju, Republic of Korea) were used in this study 
and housed under a 12-hr light/dark cycle with food and water given ad libitum. 
All procedures for animal experiments were approved by the Committee for the 
Care and Use of Laboratory Animals at Yonsei University Health System and 
performed according to the National Institute of Health guidelines for the Care 
and Use of Laboratory Animals.  
AICAR (sc-200659, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was 
dissolved in saline. For subchronic experiments, mice were injected 
intraperitoneally (i.p.) with a dose of 125 mg/kg/day AICAR or saline vehicle, 
for 7 days. Injections were performed from 10:00 am to 12:00 pm and behavior 
tests were performed 3 hr after injection. Mice were sacrificed on the 7th day, 
about 5 hr after last drug treatment (Fig. 1). The number of mice in the first 
subchronic experiment was 6 per group, and additional 4 mice per group were 
used in the second experiment for analysis of muscle. For the results of neuronal 
tissues, data from a total of 10 mice per group were pooled to be analyzed since 
the direction of changes in neuronal AMPK activity upon AICAR treatment in 
young mice were the same in both the first (n = 6 per group) and second (n = 4 
per group) cohorts. For acute experiments, AICAR (25 nM) or saline was 
administered intracerebroventricularly (i.c.v.) at a rate of 0.2 µL/min by 
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stereotaxic injection using a Hamilton syringe at the coordinates of 0.2 mm 
posterior, 1.0 mm lateral, and 3.1 mm deep from bregma. Surgery was performed 
under isoflurane anesthesia (2.0% isoflurane in 30% oxygen and 70% nitrous 
oxide using a facemask). Brains were extracted about 3 hr after i.c.v treatment. 
The number of mice in acute experiment was 3 per group. 
 
 
 
 
Figure 1. Schematic representation of the behavioral test and drug 
treatment. Mice were treated with vehicle (control) or 125 mg/kg/day AICAR 
intraperitoneally for 7 days, and tested in the eight-arm maze 3 hr after the 
injection every day.  
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2. Behavioral test: the eight-arm maze 
 
The eight-arm maze tests and data processing were performed as described 
previously.35 The maze was slightly modified size of version for mice,47 which 
consisted of eight arms (32 cm long × 4cm wide × 4cm high) extending radially 
from an octagonal central platform (18 cm in diameter). The apparatus was 
transparent and surrounded by various and consistent extramaze cues such as a 
chair, bottles and laboratory benches. Mice were water-deprived overnight, and 
50 µl of water was presented as a reward at the end of each arm. Mice were placed 
in the maze 3 hr after drug treatment for 7 consecutive days (Fig. 1). The test 
ended when the mice: entered into all 8 arms, or entered any arm 24 times 
whichever comes first. Overall performance score during the whole test period 
was determined by the area under the curve (AUC) analysis utilizing the formula: 
6 × (average number of entries of each group in day 1) − (number of entries of 
each mouse in day 2 + day 3 + day 4 + day 5 + day 6 + day 7). 
 
3. Western blot analysis 
 
For western blot analysis, hippocampi and right anterior quadriceps muscle 
were immediately dissected and prepared after sacrifice of animals. Hippocampal 
and muscle tissues were homogenized in lysis buffer consisting of: 20 mM Hepes 
(pH 7.0), 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol 
tetraacetic acid, 10 mM KCl, 1.5 mM MgCl2, 250 mM sucrose, and cocktails of 
phosphatase inhibitors and protease inhibitors. Homogenates were centrifuged at 
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8,000 × g for 30 min. Equal amounts of each protein sample were resolved on 8% 
SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Millipore, 
Bedford, MA). After blocking, membranes were probed overnight at 4°C with 
the following antibodies: anti-Thr172-phosphorylated AMPKα (p-AMPK; 
1:1,000, 2531s, Cell Signaling Technology, Beverly, MA, USA), anti-AMPKα 
(1:1,000, 2603s, Cell Signaling Technology). Membranes were washed and 
incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1:5,000, 
7074s, Cell Signaling Technology) for 1 hr at room temperature (RT), followed 
by enhanced chemiluminescence detection (ECL plus; Amersham Biosciences, 
Piscataway, NJ, USA). Measurement of signal intensity was done by Multi Gauge 
3.0 analysis software (FUJIFILM, Tokyo, Japan). Signal intensity of p-AMPK 
was normalized by that of total AMPK, and the absolute value of p-
AMPK/AMPK ratio was converted to relative values by the reference value (p-
AMPK/AMPK set as 1 from a randomly selected, young control mouse). 
 
4. ATP assay 
 
  ATP assays were performed once with hippocampi, which were dissected 3 hr 
after i.c.v. drug treatment. Fresh hippocampal tissues were homogenized with 
sterilized ice-cold phosphate-buffered saline (PBS). Homogenates were 
centrifuged for 30 sec and supernatants were transferred into new tubes. The 
supernatant (10 µl) was analyzed for ATP levels using the colorimetric ATP assay 
kit (BioVision, Mountain View, CA, USA). The remaining supernatant was 
quantified for protein analysis. Concentration of ATP was presented as amount of 
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ATP per mg of protein. 
 
5. Assessment of neurogenesis 
 
  For analysis of neurogenesis in vivo, 5-bromo-2-deoxyuridine (BrdU; B5002, 
Sigma-Aldrich Co., St. Louis, MO, USA) was injected i.p. at a dose of 100 
mg/kg/day for 7 consecutive days. Mice were anesthetized and transcardially 
perfused with 4% paraformaldehyde (PFA). The brains were removed and post-
fixed overnight in 4% PFA followed by equilibration in 15% and 30% sucrose for 
24 hr each. Tissues were then quick-frozen in optimal cutting temperature 
compound (Sakura Finetek, Zoeterwoude, the Netherlands) and cut coronally into 
30 µm sections through the anteroposterior extension of the hippocampi using a 
cryostat. Every sixth section from each brain was mounted onto gelatin-coated 
slides and processed for immunohistochemistry. I pretreated sections for 
permeabilization (with 0.3% Triton-X-100 in PBS at RT for 1 hr), and quenching 
(with 3% H2O2 in methanol at RT for 40 min). For BrdU staining, I performed 
DNA denaturation (with 2× saline-sodium citrate/50% formamide at 65°C for 2 
hr and 2N HCl at 37°C for 30 min, followed by a rinse in 100 mM sodium borate 
pH 8.5) on pretreated-sections. Sections were then washed with PBS and blocked 
for 1 hr with Mouse on Mouse (MOM) blocking solution (MOM kit, BMK-2202, 
Vector Laboratories, Burlingame, CA, USA). Afterward, sections were again 
washed with PBS, incubated for 5 min with diluent solution (MOM kit) and then 
incubated for 1.5 hr with a mouse anti-BrdU antibody (1:200, B8434, Sigma-
Aldrich Co.). Next, sections were again washed with PBS and incubated for 30 
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min with the secondary antibody biotinylated anti-mouse Ig (1:250, MOM kit, 
Vector Laboratories). For doublecortin (DCX) staining, pretreated-sections were 
blocked for 1 hr with 3% bovine serum albumin (BSA; Sigma-Aldrich Co.), 
followed by incubating with a goat anti-DCX antibody (1:200, sc-8066, Santa 
Cruz Biotechnology) overnight. Then, sections were washed with PBS and 
incubated for 1 hr with a biotinylated anti-goat IgG (1:250, BA-9500, Vector 
Laboratories). For both immunostaining, immunoreactive sites were visualized 
using the Vectastain ABC kit (Vector Laboratories) and the Ni-DAB (Vector 
Laboratories) method. Counterstaining was done with nuclear fast red (Vector 
Laboratories). After immunostaining, the cryostat sections were imaged with a 
light microscope (Olympus, Pennsylvania, PA, USA). The cells that were positive 
for BrdU or DCX were counted in the dentate gyrus (DG; including the granular 
and subgranular zone) in the 40 x magnified images. DCX positive cells were 
counted only if they had extended neural process at least to a minimal degree. 
Counting was performed by who was blind to treatment and age conditions. Total 
number of positive cells in the whole hippocampus of each animal was calculated 
by multiplying 6 by the number of positive cells summed up from every sixth 
section from a single hippocampus. 
 
6. BDNF immunohistochemistry 
 
  Fixed coronal hippocampal sections were permeabilized in PBS with 0.3% 
Triton-X-100 and stained in free-floating conditions. After blocking, sections 
were incubated with the primary antibody goat anti-BDNF (1:200, sc-546, Santa 
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Cruz Biotechnology) in PBS containing 2% bovine serum albumin and 0.3% 
Triton-X-100 at 4°C overnight. After washing with PBS three times, slices were 
labeled with the secondary antibody donkey anti-goat Alexa Fluor® 488 (705-
546-147, Jackson Immuno Research Laboratories, West Grove, PA). Cells were 
counter-stained with 4’,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) and 
observed under a confocal laser-scanning microscope (Carl Zeiss, Jena, 
Germany). The fluorescence intensity was quantified in a 20 x magnified field 
containing each hippocampal subfield (CA1, CA3 and DG) using Zen 2012 
imaging software (Carl Zeiss MicroImaging GmbH, Germany). Measurement 
was performed by an experimenter blind to age or treatment condition. Values 
were corrected for background intensity in the selected field area for each section. 
 
7. Statistical analysis 
 
  I conducted 2x2 factorial Analysis of Variance (ANOVA) with factors as age 
(young versus old) and treatment (saline versus AICAR). For post hoc 
comparison between saline and AICAR treatment within each group of the same 
age, t-test were used with unadjusted p-value. Correlations were evaluated by 
Pearson’s correlation analysis. Bar graphs indicate mean ± standard error (SE). 
Statistical significance was set at two-tailed p < 0.05. All analyses were 
performed using SPSS 20 (IBM Corp., Armonk, NY, USA). 
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III. RESULTS 
 
1. Improvement in cognition upon AICAR treatment was attenuated in old 
versus young mice 
 
  I first examined the effect of AICAR treatment on cognitive function in old 
versus young mice using the eight-arm maze.35 For 7 days, mice were daily i.p. 
injected with a dose of 125 mg/kg/day AICAR or saline and performed the maze 
test 3 hr after the injection (Fig. 1). Evaluating overall effect of treatment on 
cognitive performance throughout the 7 days using area AUC analysis, I found 
the main effect of treatment [F (1, 28) = 5.769, p = 0.023] and of age x treatment 
interaction [F (1, 28) = 6.270, p = 0.018] on cognitive improvement in 2-way 
ANOVA. Age itself had no significant effect [F (1, 28) = 1.632, p = 0.212]. 
AICAR treatment had a significant effect on cognition in young mice (t = -3.213, 
p = 0.006; Fig. 2a) but not in old mice (t = 0.079, p = 0.938; Fig. 2a). 
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Figure 2. Cognitive improvement and response of hippocampal and 
muscle AMPK upon subchronic AICAR treatment in old versus young 
mice.  
Mice were given vehicle (control) or AICAR (125 mg/kg/day) intraperitoneally 
for 7 days. Cognitive improvement was tested in the eight-arm maze. (A) The 
overall performance on the eight-arm maze was formulated as AUC (n = 
8/group). A higher AUC value indicates better performance. AMPK expression 
and phosphorylation on Thr172 were analyzed by Western blot on the final day 
of drug administration. (B) Entire hippocampus (n = 10/group). (C) Right 
anterior quadriceps muscle (n = 4/group). AUC, Area under the curve. Main 
effect of age, treatment, and age x treatment interaction was analyzed by 2-way 
ANOVA. # p < 0.05 for interaction. The effect of treatment within each age-
group by t-test (unadjusted). * p < 0.05, ** p < 0.01. Each bar, mean ± SE.  
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2. Response of hippocampal and muscle AMPK upon AICAR treatment 
attenuated in old versus young mice  
 
I hypothesized that the age-associated difference in cognition with AICAR 
treatment could be attributed to attenuated AMPK activation in older brains. 
Therefore, I measured changes in hippocampal AMPK activity upon AICAR 
treatment in young and old mice by assessing the ratio of p-AMPK to total AMPK. 
In 2-way ANOVA, I found no statistically significant main effect of age [F (1, 36) 
= 1.814, p = 0.186] or of treatment [F (1, 36) = 1.368, p = 0.25] on the levels of 
hippocampal AMPK activity. Age x treatment interaction was not significant [F 
(1, 36) = 2.421, p = 0.128; Fig.1a]. However, as can be seen in Fig. 2b, the 
direction of change in p-AMPK levels following AICAR treatment seemed to be 
directly opposite to my expectation in young mice (for reference, t = 3.371, p = 
0.003, unadjusted for potentially multiple comparisons; Fig. 2b). Therefore, I 
proceeded to an additional experiment with the small number of animals (n = 4 
per group) to see the changes in AMPK activity by AICAR in the skeletal muscles 
as well. This was to confirm whether 7-days i.p. AICAR treatment had been 
pharmacologically valid and provided results consistent with previous reports 
using the skeletal muscles or liver tissues.45,46 In the levels of muscle AMPK 
activity, significant main effect of age [F (1, 12) = 32.666, p < 0.001] and age x 
treatment interaction [F (1, 12) = 7.417, p = 0.018; Fig. 2c] were observed. 
Treatment [F (1, 12) = 3.548, p = 0.084] showed no significant main effect. In 
addition, the direction of changes in AMPK activity upon AICAR treatment was 
‘increase’ in young mice (t = -2.455, p = 0.049; Fig.2c), which was different from 
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the findings of the hippocampus. Highly consistent with the previous report,46 
this finding confirmed that AICAR administration was pharmacologically valid 
in experimental animals of this study. 
 
3. Cognitive function inversely correlated with hippocampal AMPK activity  
    
To address the contextual meaning of the reduced activity of hippocampal 
AMPK in young mice after AICAR treatment, I examined the relationship 
between AMPK activity and cognitive scores. Interestingly, I found a significant 
inverse correlation between cognitive function and hippocampal p-AMPK levels 
in young mice (r = -0.599, p = 0.040; Fig. 3a), although this correlation was not 
observed in old mice (r = -0.077, p = 0.812; Fig. 3a) or entire mice (r = -0.305, 
p = 0.148; Fig. 3a). Muscle AMPK activity and cognitive function showed: 
significant positive correlation in entire mice (r = 0.600, p = 0.014; Fig. 3b), a 
trend level in young mice (r = 0.665, p = 0.072; Fig. 3b), and no correlation in 
old mice (r = 0.249, p = 0.553; Fig. 3b). These results further support the 
hypothesis that cognitive improvement in young mice is associated with reduced 
activity of neuronal AMPK upon AICAR treatment, although there is likelihood 
of involvement of muscle AMPK as well.  
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Figure 3. Correlation between cognitive function and AMPK activity of 
hippocampus and muscle. Seven days after drug administration, relative 
hippocampal p-AMPK levels and AUC analysis of performance on the eight-
arm maze showed: a positive correlation in young mice, but no correlation in 
the old and entire mice. In the muscle, relative p-AMPK levels and AUC score 
showed: a positive correlation in entire mice, a trend level in young mice, and 
no correlation in the old mice. Correlation by Pearson’s correlation test. Lines 
and r values indicate the regression of data (black solid, entire mice; blue 
dashed, young mice; red dotted, old mice). AUC, Area under the curve.  
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4. ATP levels inversely correlated with hippocampal AMPK activity  
 
  Based on the unexpected finding of the decreased hippocampal p-AMPK level 
and inverse relationship between hippocampal AMPK activity and cognitive 
function in young mice upon AICAR treatment, I speculated that a reduction in 
neuronal AMPK activity might indicate a higher energy state induced by AICAR 
treatment. That is, if AICAR improved cognition in young mice by successfully 
promoting ATP production through AMPK signaling, then AMPK activity per se 
might be deactivated by the increase in ATP levels. To test this hypothesis, I 
examined the relationship between ATP levels and AMPK activity upon acute 
AICAR treatment. In this experiment, I used i.c.v. AICAR injection instead of i.p. 
injection to minimize the secondary effects of AICAR-induced changes in 
peripheral metabolism on hippocampal AMPK. I found a strong inverse 
relationship between hippocampal AMPK activity and ATP levels (r = -0.719, p 
= 0.008; Fig. 4a) regardless of age or treatment. In regard to each age group, there 
was a trend level of inverse correlation in young mice (r = -0.793, p = 0.060; Fig. 
4a), but no correlation was shown in old mice (r = -0.552, p = 0.256; Fig. 4a).  
   
When it comes to the AMPK activity, acute i.c.v. AICAR injection showed 
significant age x treatment interaction [F (1, 8) = 8.283, p = 0.021; Fig. 3b. Also 
see Supplementary Table 1], which indicates blunted AMPK response in old mice. 
The direction of hippocampal AMPK activity in young mice was also ‘decreased’ 
in accordance with the result from the 7-day systemic (i.p.) treatment.  
Regarding the changes in ATP levels, although it seemed that AICAR increased 
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the mean value only in young mice (Fig. 4c), no significant interaction between 
age and treatment [F (1, 8) = 1.415, p = 0.268; Fig. 4c. Also see Supplementary 
Table 1].  
   
Although still elusive to draw a conclusion from this additional experiment with 
the small number of samples, results from the correlation analyses could suggest 
that ATP-AMPK feedback loop might indeed exist, and, if so, it would be only 
apparent in young mice. At least, it was revealed here that response of AMPK 
was blunted in old mice compared to young mice upon direct AICAR injection 
into the brain.    
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Figure 4. ATP levels inversely correlated with hippocampal AMPK activity.  
Mice were treated intracerebroventricularly with vehicle (control) or 25 nM 
AICAR injection and decapitated 2.5 hr after drug administration. In the 
hippocampus: (A) correlations between ATP level and relative p-AMPK level 
were analyzed by Western blot analysis, (B) AMPK expression and 
phosphorylation on Thr172 were analyzed by Western blot analysis (n = 3/group), 
and (C) ATP levels (nmol/mg protein) were analyzed using a colorimetric ATP 
assay kit (n = 3/group). Correlation by Pearson’s correlation test. Line and r 
value indicate the regression of the dataset (black solid, entire mice; blue 
dashed, young mice; red dotted, old mice). Main effect of age x treatment 
interaction by 2-way ANOVA. # p < 0.05 for interaction. The effect of 
treatment within each age-group by t-test (unadjusted). * p < 0.05. Each bar, 
mean ± SE.  
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5.  Neurogenesis upon AICAR treatment attenuated in old versus young 
mice 
 
  Next, I explored the changes in potential mediators between AMPK and 
cognition, as downstream effectors of AMPK. Based on a previous report 
showing that AICAR enhances cognitive function via AMPK-dependent 
increases in hippocampal neurogenesis,35 I compared the levels of AICAR-
induced neurogenesis in young versus old mice. For 7 days, mice were daily i.p. 
injected with a dose of 125mg/kg/day AICAR and 100mg/kg/day BrdU. After 7 
days of drug treatment, 2-way ANOVA of number of BrdU- and DCX- 
immunoreactive cells in the hippocampus revealed a significant main effect of 
age [BrdU, F (1, 11) = 487.2, p < 0.001; DCX, F (1, 11) = 711.407, p < 0.001] 
and a significant age x treatment interaction [BrdU, F (1, 11) = 7.564, p = 0.019; 
DCX, F (1, 11) = 5.504, p = 0.046; Fig. 5. Also see Supplementary Table 1]. 
These results suggest that AMPK-dependent increases in neurogenesis might be 
associated with cognitive improvement, as I observed both results only in young 
mice (Fig. 2a and Fig. 5). 
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Figure 5. Enhanced neurogenesis upon AICAR treatment was attenuated 
in old versus young mice. Representative photomicrographs of BrdU (A) and 
DCX (B) positive cells in the hippocampus after 7-day BrdU (100 mg/kg/day) 
and AICAR (125 mg/kg/day) injections. Top line, 10×. Bottom line, 40×. Scale 
bar indicates 100 µm. Number of BrdU (C) and DCX (D) positive cells per 
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dentate gyrus (n = 3–4/group). BrdU, 5-bromo-2’-deoxyuridine; DCX, 
doublecortin. Main effect of age (BrdU, p < 0.001; DCX, p < 0.001) and 
treatment (BrdU, p = 0.126; DCX, p = 0.017), and age x treatment interaction 
(BrdU, p = 0.019; DCX, p = 0.046) by 2-way ANOVA. # p < 0.05 for 
interaction. The effect of treatment within each age-group by t-test (unadjusted). 
* p < 0.05. Each bar, mean ± SE.  
 
6. BDNF expression with AICAR treatment attenuated in old versus young 
mice 
 
BDNF is a crucial signal for neurogenesis and is upregulated by AMPK42,48; 
therefore, I investigated whether the effect of AICAR treatment on hippocampal 
BDNF expression also differed between young and old mice. In the CA3 region 
of hippocampi, significant main effect of age and treatment [age, F (1, 19) = 
12.345, p = 0.002; treatment, F (1, 19) = 13.526, p = 0.002; Fig. 6a and 6c] were 
shown on the level of BDNF immunoreactivity, with significant age x treatment 
interaction [F (1, 19) = 11.726, p = 0.003; Fig. 6a and 6c]. These results suggest 
that AICAR treatment significantly increased BDNF expression in CA3 only 
from young mice, but not old mice. However, such age x treatment interaction 
was not observed in other hippocampal regions [CA1, F (1, 20) = 0.141, p = 0.711; 
DG, F (1, 19) = 3.261, p = 0.087; Fig 6a, 6b and 6d], with only significant main 
effect of age in DG [F (1,19) = 6.993, p = 0.016, see Supplementary Table 1]. 
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Figure 6. Enhanced BDNF expression upon AICAR treatment was 
attenuated in old versus young mice. (A) Representative confocal images of 
hippocampal sections incubated with a BDNF antibody (Blue, DAPI; Green, 
BDNF). Scale bar indicates 100 µm. Measured immunoreactivity of BDNF in 
the CA1 (B), CA3 (C), and DG (D) after daily intraperitoneal AICAR (125 
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mg/kg) injection for 7 consecutive days (n = 3–4/group). BDNF, Brain-derived 
neurotrophic factor; DAPI, 4’,6-diamidino-2-phenylindole; CA, cornus 
ammonis; DG, dentate gyrus. Main effect of age (CA1, p = 0.37; CA3, p = 
0.002; DG, p = 0.016) and treatment (CA1, p = 0.129; CA3, p = 0.002; DG, p 
= 0.096), and age x treatment interaction (CA1, p = 0.711; CA3, p = 0.003; DG, 
p = 0.087) by 2-way ANOVA. ## p < 0.01 for interaction. 
 
 29 
IV. DISCUSSION 
 
  In this study, I tested my hypothesis that reduced activation of neuronal AMPK 
in old age could cause cognitive aging. Using AICAR as an AMPK activator, I 
found that significant responses in AICAR-induced AMPK activity occurred in 
the young, but not in old, mice upon acute i.c.v. AICAR treatment, although this 
age-related difference was not prominent in subchronic treatment. The effects of 
subchronic AICAR treatment were still found diminished on cognitive function, 
neurogenesis, and BDNF expression in old mice compared to young mice. These 
results suggest that cognitive aging may be considered a form of neuronal 
bioenergetic failure that could become overt with increased cognitive and 
metabolic demands.  
 
  A reduced response of AMPK and AMPK-related signals upon AICAR 
treatment has been previously identified in the muscle and liver tissues of old 
mice.45,46 In these studies, the authors suggest that the reduction in AMPK activity 
could be a causative factor for aging-associated metabolic dysfunction.45,46 In the 
current study, I found evidence that attenuated AMPK responses in old age also 
may account for aging-associated neuronal dysfunction (Fig. 7). In this regard, 
my study suggests that not only developing novel AMPK activators but also 
enhancing the sensitivity of AMPK could be a key strategy to alleviate age-
related reduction in neurogenesis and subsequent cognitive decline.  
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Figure 7. Working hypothesis of the attenuated response of neuronal 
AMPK and cognitive aging. Schematic representation of the sensitivity of 
neuronal AMPK and cognitive aging. In young mice, AICAR-induced 
neuronal AMPK activation successfully increased the level of ATP, which in 
turn reduced AMPK activity. In old mice, the response of neuronal AMPK and 
other related pathways attenuated, which may account for cognitive aging. In 
terms of the BDNF expression and neurogenesis, both of them were not 
meaningfully increased by AICAR in old age. Although these results could 
together indicate that the blunted AMPK response (reduced BDNF expression) 
may be responsible for reduced neurogenesis in old age, region-specific, direct 
relationship between BDNF and neurogenesis was not supported by our 
findings that showed significant increases in each component occurred in 
different regions (CA3 and DG, respectively) in young mice (see the text). 
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Surprisingly, the direction of the AICAR-induced change in AMPK activity was 
different between the hippocampal and skeletal muscle tissues in young mice. 
Upon AICAR treatment, p-AMPK levels were increased in muscle, but 
seemingly reduced in the hippocampus. Such a reduction in neuronal AMPK 
activity could be interpreted as a rapid deactivation rather than a direct inhibition, 
by AICAR. The inverse relationship between ATP levels and hippocampal 
AMPK activity observed after i.c.v. AICAR injection supports this speculation. 
Increased ATP levels may be caused by an AICAR-induced increase in oxidative 
phosphorylation via the mitochondria, because AMPK stimulates mitochondrial 
biogenesis and ATP production.49 In addition, given the previous report that 
deactivation of AMPK occurred in approximately 40 min following AICAR 
treatment in vitro,50 5 hr after i.p. injection or 3 hr after i.c.v. injection in my 
experiment might be long enough for the feedback mechanism to be apparently 
working. 
 
  An explanation for the difference between AMPK activity in neuronal and 
muscle tissues is beyond the scope of this study; however, I speculate that this 
difference might stem from the unique characteristics of neuronal tissue. 
Neuronal tissues may be vulnerable to prolonged activation or over-activation of 
AMPK, compared with other tissues.51-53 Therefore, they may have an innate 
defense mechanism to avoid unwanted off-target adverse effects beyond meeting 
54metabolic demands. 
 
Another important question that I have had was how senescence reduces 
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response of AMPK. In this study, we could not certainly identify whether the 
function of downstream pathways of AMPK changed by aging, but we showed 
reduced sensitivity of AMPK itself in brain as well as muscles. Although definite 
reason of its reduced sensitivity has not been found yet, several reports have 
provided clues about possible underlying mechanisms of aging-associated 
reduction of AMPK response. Aging-related functional changes of protein 
phosphatases such as PP2A, PP2Cα or PPm1E, which are involved in the 
suppression of AMPK activation,55,56,57 could be one cause of reduced 
responsiveness. In addition, given that anti-inflammatory agent did a role of 
potent AMPK activator,58,59 chronic inflammatory environment in aged tissue 
might incapacitate sensitivity of AMPK. Another possible mechanism shown by 
Shao et al.(2014)60 is that AMPK transforms into oxidized aggregates because of 
intermolecular disulfide bonds formed under oxidative stress, which negatively 
regulates AMPK activity. Further studies which verify the mechanism of age-
related attenuation of sensitivity of AMPK are needed to identify the connection 
of neurometabolism and cognitive aging. 
 
  This study has several limitations. First, I only used AICAR to modulate 
AMPK activity. An extended study using AMPK inhibition such as a functional 
knock-out system would be crucial to show a direct causal relationship between 
AMPK activity and neurogenesis or BDNF expression, although several previous 
studies have been supporting such relationships.36,61,62 On the other hand, given 
the blunted response to AICAR in old age, a study using any measure enabling 
recovery of AMPK responsiveness would successfully prove the importance of 
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AMPK involvement in cognitive aging.  
 
  Second, I only showed the results from a relatively short period of AICAR 
treatment. A recent study shows that prolonged AICAR treatment can induce 
expressions of genes related to neural development and increase cognitive 
function in both old and young mice. However, this previous study also suggested 
the concept of ‘reduction in AMPK sensitivity in old mice’, since it showed that 
a longer period of AICAR treatment was needed to improve cognition in old than 
young mice.54 Thus, the current study could be evaluated as a direct measurement 
of hippocampal AMPK activity in order to account for the differential effects of 
an AMPK activator on neurogenesis between young and old mice within a limited 
period of treatment. Future studies are needed to identify the molecular 
mechanisms responsible for the reduced sensitivity of AMPK in old age.  
 
  Third, to further address the unexpected finding, I explored the relationship 
between AMPK activity and ATP levels in the hippocampus following directly 
injecting AICAR into the ventricles. Although I indeed found the inverse 
correlation between them, more comprehensive interpretation of data from this 
acute experiment should be cautious due to the small number of animals used. 
For example, following this acute injection, AMPK activity in old age was shown 
comparably as high as in young age, which is elusive to draw logical conclusion. 
Additionally, since I determined to measure ATP levels to see the potential 
feedback loop between ATP and AMPK by acute i.c.v. injection of AICAR, I 
could not further address the issue with the data from muscle tissue, which would 
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be able to broaden our understanding of the timing and dynamics in the feedback 
loop across different kinds of tissues. 
 
  Fourth, originally, I intended to examine the changes in BDNF levels upon 
AICAR treatment under a hypothesis that BDNF is a potential candidate that may 
mediate the link between reduced AMPK action and neurogenesis in old age since 
BDNF is induced by AMPK activation and enhances neurogenesis. However, 
besides the methodological limitations in using immunohistochemistry for 
quantification of protein expressions, my results failed to support the region-
specific link between reduced BDNF and neurogenesis in old age. The significant 
changes in each component were identified in different subregions in the 
hippocampus; significant changes in neurogenesis were identified in DG while 
changes in BDNF levels only significant in CA3 region upon AICAR treatment. 
Therefore, these findings suggest that CA3-BDNF expression may be an 
independent factor from the changes in DG-neurogenesis upon AICAR treatment. 
However, the finding of blunted change in BDNF expression in old age may still 
support the age-related reduction in responsiveness of AMPK as BDNF 
expression is stimulated by AMPK. In addition, several previous studies have 
suggested the possible link between BDNF expression in CA3 and neurogenesis 
in DG enhanced by exercise, diet restriction, or antidepressants.22,63,64 Thus 
further studies are warranted to elucidate the region-specific relationship between 
AMPK, BDNF, and neurogenesis regarding aging process. 
 
Fifth, my study could not determine whether AMPK activation in the brain was 
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mediated directly by AICAR or secondary to peripheral effects of AICAR54 for I 
did not measure brain concentration of AICAR following i.p. injection. A positive 
correlation between muscle p-AMPK and cognitive function (Fig. 3b) could also 
raise a question about peripheral effects. However, although the permeability of 
the blood brain barrier by AICAR has been known to be relatively low,65 there 
have been several studies which demonstrated activation of brain AMPK by 
systemic AICAR administration.35,66 In addition, not only systemic injection35,54 
but also direct i.c.v. injection of AICAR67 was verified to improve cognitive 
function, showing the involvement of AMPK in cognition. 
 
Lastly, I have not investigated the fundamental reason of aging-associated 
attenuation of AMPK. Further studies, which traces the underlying molecular 
mechanisms of blunted responsiveness of AMPK, could have an implication on 
the research of aging-associated metabolic dysfunction.  
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V. CONCLUSION 
 
This study showed that an aging-associated reduction in hippocampal AMPK 
sensitivity might be an underlying molecular account of cognitive aging, which 
is paralleled by a decrease in neurogenesis and BDNF expression in old mice. 
Blunted AMPK response in old age is a new finding regarding brain tissue, 
corroborating previous findings in peripheral tissues.45,46 What I have found 
through this study is,  
 
1. AICAR improves cognitive function only in young mice, not in old 
mice.  
 
2. AICAR-induced change in hippocampal AMPK activity was blunted in 
older mice. 
 
3. AICAR increased neurogenesis and BDNF expression in young, but 
not in old mice. 
 
4.  Blunted AMPK activation may account for age-related reduction in 
neurogenesis and subsequent cognitive decline. 
 
5. Recovering AMPK responsiveness may be key to enhance cognitive 
aging.  
 
 37 
These results imply that the activation of neuronal AMPK to meet cognitive and 
neurometabolic demands may be diminished in old age. Thus, further studies 
should focus on a strategy to recover the sensitivity of AMPK in old age and 
determine the therapeutic potential of AMPK activation in preventing or 
alleviating cognitive decline with aging. 
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Supplementary table 1. Statistics of results by 2x2 factorial ANOVA with 
factors as age and treatment. 
 
2x2 factorial ANOVA with factors as age (young versus old) and treatment (saline versus AICAR) was conducted. 
ANOVA, Analysis of Variance; AUC, Area under the curve; BrdU, 5-bromo-2’-deoxyuridine; DCX, doublecortin; 
CA, cornus ammonis; DG, dentate gyrus. Statistically significant results (set as p < 0.05) were indicated as bold and 
asterisks.  
 Variable  Factor F df p 
Figure 2a Entries (AUC) 
 
Age 1.632 1, 28 0.212 
Treatment* 5.769 1, 28 0.023 
Age x Treatment* 6.270 1, 28 0.018 
Figure 2b Hippocampal  
p-AMPK/AMPK 
Age 1.814 1, 36 0.186 
Treatment 1.368 1, 36 0.25 
Age x Treatment 2.421 1, 36 0.128 
Figure 2c Muscle  
p-AMPK/AMPK 
Age* 32.666 1, 12 <0.001 
Treatment 3.548 1, 12 0.084 
Age x Treatment* 7.417 1, 12 0.018 
Figure 4b Hippocampal  
p-AMPK/AMPK 
Age 2.718 1, 8 0.138 
Treatment 0.181 1, 8 0.682 
Age x Treatment* 8.283 1, 8 0.021 
Figure 4c Hippocampal  
ATP 
Age 3.298 1, 8 0.107 
Treatment 0.555 1, 8 0.478 
Age x Treatment 1.415 1, 8 0.268 
Figure 5c Number of  
BrdU positive cells 
Age* 487.2 1, 11 <0.001 
Treatment 2.744 1, 11 0.126 
Age x Treatment* 7.564 1, 11 0.019 
Figure 5d Number of  
DCX positive cells 
Age* 711.407 1, 11 <0.001 
Treatment* 7.839 1, 11 0.017 
Age x Treatment* 5.054 1, 11 0.046 
Figure 6b BDNF 
immunoreactivity  
in CA1 
Age 0.842 1, 20 0.370 
Treatment 2.505 1, 20 0.129 
Age x Treatment 0.141 1, 20 0.711 
Figure 6c BDNF 
immunoreactivity  
in CA3 
Age* 12.345 1, 19 0.002 
Treatment* 13.526 1, 19 0.002 
Age x Treatment* 11.726 1, 19 0.003 
Figure 6d BDNF 
immunoreactivity  
in DG 
Age* 6.933 1, 19 0.016 
Treatment 3.069 1, 19 0.096 
Age x Treatment 3.261 1, 19 0.087 
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ABSTRACT (IN KOREAN) 
 
해마의 AMP-activated protein kinase의 반응성 감소 
: 인지 노화의 신경대사적 원인 
< 지도교수 : 김 어 수 > 
연세대학교 대학원 의학과 
 
장 수 아 
 
 
   최근 노인 인구가 증가함에 따라, 노후의 삶의 질과 건강 전반에 
큰 영향을 끼치는 인지 노화에 대한 중요성이 커지고 있다. 이러한 
인지 노화의 원인으로, 노화에 따른 신경 세포 에너지 대사의 손상이 
중요한 역할을 한다고 알려져 왔다. AMP-activated protein kinase 
(AMPK) 는 에너지 항상성 조절에 결정적인 역할을 하는 효소이며, 
AMPK 의 적절한 활성은 에너지 대사 요구를 만족시키기 위해 
필수적이다. 그러나 최근, 말초 조직에서 에너지 스트레스나 
활성촉진물질에 대한 AMPK의 반응성이 노화에 따라 감소한다는 것이 
보고되었다. 이러한 결과는 다양한 조직에서 노화에 따른 
생물에너지대사의 장애를 설명하는 실마리가 될 수 있다. 따라서, 본 
연구에서는 뇌 조직에서 AMPK 반응성이 감소하는지에 대한 여부와, 
그러한 반응성의 변화가 인지 노화와 관계가 있는지에 대해 밝히고자 
하였다. 이를 위해, 16주령의 젊은 쥐와 72주령의 고령 쥐에게 7일간 
복강내로 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR; 
AMPK 활성제) 혹은 생리식염수 (대조군) 을 투여한 후 매일 eight-
arm maze 를 이용해 인지 기능을 평가하였다. AICAR는 젊은 쥐에서만 
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인지 기능을 향상시켰고 고령의 쥐에서는 효과가 없었으며, 이를 
통해 인지 기능에 대한 AMPK 의 활성 효과가 고령 쥐에서 둔화된 
것을 알 수 있었다. 또한, AICAR 투여시 급성 뇌실내 주입 실험에서 
젊은 쥐에게서만 AMPK 그 자체의 활성도 변화가 있었으며, 고령의 
쥐에서는 아만성, 급성 실험 모두에서 변화가 없었다. 흥미롭게도, 
AICAR 에 의한 AMPK 활성의 변화 방향이 해마 (감소) 와 골격근 
(증가) 에서 반대였다. 게다가 해마의 AMPK 활성도는 인지 기능 
점수와 역상관성을 보였다. 젊은 쥐에서 AICAR 처치로 인해 높아진 
에너지가, 신경세포의 AMPK 를 탈활성화시켰을 것이라 가설을 세운 
연구진은 급성 뇌실강내 AICAR 주사 후 에너지 변화 여부를 보기 
위해 ATP를 측정했다. 예상대로, ATP 는 해마의 AMPK 활성도와 
역상관성을 보여, AICAR에 의한 인지 향상에 ATP 가 기여했을 
가능성을 보여주었다. 또한, AICAR 에 의한 신경세포 발생과 brain-
derived neurotrophic factor (BDNF) 발현도 젊은 쥐에서만 증가하여, 
노화에 따른 AMPK 의 반응성 감소의 영향을 확인할 수 있었다.  
본 연구는, AMPK 의 반응성 저하가 ATP, BDNF 발현, 신경세포 발생의 
촉진을 저해하여, 인지 노화의 신경대사적인 원인이 될 수 있음을 
시사한다. 이 연구는, AMPK의 활성을 높이는 것 뿐만 아니라, 
반응성을 회복하는 것이 인지 노화의 개선에 중요할 수 있음을 
제시하는 데 의의가 있다고 본다.  
 
 
 
 
---------------------------------------------------------------- 
핵심되는 말: AMPK, 인지 노화, 신경대사, 신경세포 발생, BDNF, 해
마  
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